Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 7/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.38 |
| ▸ | WNT3A | P56704 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14194548 | 0.77 | NSD2 (0.41) | ALDH1A1SRD5A2CTNNB1WNT3AMAPT | |
| SCHEMBL4851383 | 0.76 | ALDH1A1 (0.39) | ALDH1A1CTNNB1WNT3AXDHSLC22A12 | |
| SCHEMBL29915036 | 0.69 | PARP1 (0.41) | ALDH1A1KDM4EMAPT | |
| SCHEMBL27002417 | 0.69 | PARP1 (0.41) | ALDH1A1KDM4EMAPT | |
| SCHEMBL31262479 | 0.68 | CTNNB1 (0.67) | ALDH1A1CTNNB1WNT3ANPC1RAB9A | |
| SCHEMBL875455 | 0.68 | CTNNB1 (0.67) | ALDH1A1CTNNB1WNT3ANPC1RAB9A | |
| SCHEMBL4733998 | 0.68 | MAOB (0.38) | NPC1RAB9AXDHSLC22A12MAPT | |
| SCHEMBL14124788 | 0.67 | ALDH1A1 (0.79) | ALDH1A1SRD5A2NPC1RAB9AKDM4E | |
| SCHEMBL14124796 | 0.67 | ALDH1A1 (0.72) | ALDH1A1SRD5A2CTNNB1WNT3ANPC1 | |
| SCHEMBL4695076 | 0.66 | PARP1 (0.38) | ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351737-B2 | 4-[(8-substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-YL-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity | ALLERGAN, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1485368-A1 | SUBSTITUTED CHROMAN DERIVATIVES HAVING CYTOCHROME P450RAI INHIBITORY ACTIVITY | Allergan, Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040077721-A1 | Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A | ALLERGAN, INC. | 2004-04-22 | — | — | US | disclosed |
| US-20030207937-A1 | 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity | ALLERGAN, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2003080594-A1 | SUBSTITUTED CHROMAN DERIVATIVES HAVING CYTOCHROME P450RAI INHIBITORY ACTIVITY | ALLERGAN, INC. (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077721-A1 | Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A | RARA, CYP2R1, RXRA | ALDH1A1 154/4885SRD5A2 202/4885CTNNB1 3935/4885 |
| US-20030207937-A1 | 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity | RXRA, RARA, CYP26A1 | ALDH1A1 60/4885SRD5A2 129/4885CTNNB1 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.